Although tolvaptan, a selective vasopressin V2 receptor antagonist, is currently the most common drug used to treat ADPKD patients and effectively suppresses increases in kidney volume12, the outcomes and side effects after long treatment durations are unclear, especially in pediatric patients. The gene discussed is AVPR2; the disease is autosomal dominant polycystic kidney disease.